A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

Who can take part

• Male/Female Chinese adult participant of an allogeneic Hematopoietic Stem Cell Transplant (HSCT)
• Has documented positive Cytomegalovirus (CMV) serostatus (CMV immunoglobulin G [IgG] seropositive) for recipient (R+) at the time of screening
• Is receiving a first allogeneic HSCT
• Is within 28 days post-HSCT at the time of randomization
• Female participant is not a Woman of Child Bearing Potential (WOCBP) or is a WOBCP who agrees to use acceptable contraception during the treatment period and for ≥28 days after the last dose of study drug

Who cannot take part

• Received a previous allogeneic HSCT
• Has a history of CMV end-organ disease within 6 months prior to randomization
• Has a documented positive result for a human immunodeficiency virus antibody (HIV-Ab) test at any time prior to randomization, or for hepatitis C virus antibody (HCV-Ab) with detectable HCV ribonucleic acid (RNA), or hepatitis B surface antigen (HBsAg) within 90 days prior to randomization
• Has received any prohibited medications within 2 days prior to initiation of treatment with Letermovir
• Is anticipated to be treated with Traditional Chinese Medicine or herbal medicine during the study treatment period and for 14 days after study medication
• Has severe hepatic insufficiency
• Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency
• Has an uncontrolled infection on the day of randomization
• Has rapidly progressing disease that requires mechanical ventilation or is hemodynamically unstable
• Has active solid tumor malignancies except localized basal cell or squamous cell skin cancer or the condition under treatment (e.g., lymphomas)
• Is a) on renal replacement therapy (e.g., hemodialysis, peritoneal dialysis) OR b) has end stage renal impairment with a creatinine clearance <=10 mL/min within 5 days prior to randomization
• Has evidence of CMV viremia at any time from HSCT procedure until the time of randomization

Other criteria

• The key inclusion and exclusion criteria include but are not limited to the following: